surgical resection Articles
-
A new model using artificial intelligence to predict recurrence after surgical resection of stage I-II non-small cell lung cancer.
Abstract Background: Five-year survival for stage I-II lung cancer is quite low even after complete surgical resection. Current guidelines recommend adjuvant treatment only for selected patients with stage II or higher disease. A prediction model that identifies patients at high risk of recurrence who may benefit from adjuvant treatment is greatly needed. Many existing prediction models include ...
-
Comparison of genomic signatures of non-small cell lung cancer recurrence between two microarray platforms
Abstract Background Cancer genomic signatures may vary using different platforms. We compared the differential gene expression in non-small cell lung cancer (NSCLC) between two platforms in order to find the most relevant genomic signatures of tumor recurrence. Materials and Methods We analyzed gene expression in frozen lung cancer tissue from 59 selected patients who had undergone surgical ...
-
Generating a robust prediction model for stage I lung adenocarcinoma recurrence after surgical resection
Abstract Lung cancer mortality remains high even after successful resection. Adjuvant treatment benefits stage II and III patients, but not stage I patients, and most studies fail to predict recurrence in stage I patients. Our study included 211 lung adenocarcinoma patients (stages I–IIIA; 81% stage I) who received curative resections at Taipei Veterans General Hospital between January ...
-
The New Guidelines For Interventional Oncology - And How Micromate™ Seamlessly Fits Into Them
Interventional Oncology, the 4th pillar of modern cancer care Until the late 90s, modern cancer care consisted of three pillars of treatment: surgery (through tumor resection), radiation therapy, and chemotherapy. These pillars address tumors directly, removing or destroying lesions. Although immunotherapy specialists devised ingenious ways to use the patients’ own immune system to better ...
-
Multifunctional Black Bioactive Ceramic Material Developed Recently
Bioceramic materials have a long history of being used to repair human hard tissues, from biologically inert materials (such as alumina and zirconia, etc.) to biological materials that are both biologically active and degradable (such as phosphate and silicate bioceramics, silicon Based bio-glass, etc.), its physiological function is no longer a simple tissue filling substitute, but a tissue ...
By Matexcel
-
GammaTile Surgically Targeted Radiation Therapy (STaRT) Improving Access to Brain Tumor Care without Compromising Outcomes
ABSTRACT Patients with brain tumors face enormous challenges after diagnosis. Many of these challenges are amplified by issues related to access to care.1‒4 Studies suggest that patients with cancer who live farther from radiation treatment centers have poorer clinical outcomes. In addition, minorities are more likely to perceive longer travel distances as a barrier, which may cause them ...
-
Intracranial Neoplasms: The Evolution of Radiotherapies
CURRENT STANDARD OF CARE FOR BRAIN TUMORS The current initial standard of care for aggressive brain tumors—whether they are primary brain tumors (ie, tumors that originate in the brain), or metastatic tumors from cancers that started outside of the brain—is resection. After surgery, a follow-up treatment, also referred to as adjuvant treatment, is often recommended to help eliminate ...
-
Discovery of Bispecific Antibodies and Immune Checkpoint Inhibitors That Kill Glioblastoma Cells and Melanoma Cells, and Block the Metastasis of Malignant Melanoma Cells to the Lung by Over 90%
Ocean Biomedical will be a wholly owned subsidiary of Aesther Healthcare Acquisition Corp. and will change its name to Ocean Biomedical, Inc., expected to be listed on NASDAQ under the symbol, “OCEA”. PROVIDENCE, R.I. and NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Ocean Biomedical and Aesther Healthcare Acquisition Corp. (“Aesther”) (NASDAQ: AEHA) ...
-
ODS Medical is a 2018 Medtech Innovator Showcase Company
Summary: In treating brain cancers, neurosurgeons face a critical decision: remove too little tissue and risk fatal recurrences or remove too much and cause profound neurological damage. Presently, they rely on pre-operative surgical navigation technologies, such as MRI, in order to determine the contours of the cancerous tissue to be safely removed. These surgical navigation systems, in ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you